Researchers use gold nanorod scattering to identify immune system's 'killer and savior'

October 20, 2020

Every biological system is naturally equipped with a defense mechanism to protect against abnormal changes caused by either local, environmental, or biochemical alteration. White blood cells (WBC) play the role of such a 'soldier' in our immune response. One type of WBC, known as macrophages, is the most efficient and specialized fighter since it is simultaneously equipped with the power of selective identification and elimination of foreign invaders, as well as the potency to repair wounds. Depending on their work distribution, macrophages are mainly comprised of two types, M1 and M2. M1 cells act as the 'professional killer', while M2 cells are more concentrated on healing activity.

In a normal, healthy situation, the immune system maintains a good balance between M1 and M2 cells. But in diseased conditions like bacterial, virus or parasite infections, or inflammations for atherosclerosis, cancer, or arthritis, the balance between M1 and M2 becomes affected, and depending on the crisis, a particular shift in M1 or M2 population occurs. If such changes could be monitored, it would lead to easy diagnostics and prediction of health conditions. There is currently no tool that can provide easy detection of M1/M2 cells directly from tissue fluid or a blood sample in a label-free manner without fluorescent tagging.

In a study just published in the journal Nano Letters, researchers from Bar-Ilan University in Israel have shown a simple solution to this issue with the help of the scattering effect of Gold Nanorods (GNRs). Gold-based nanoparticles are well known for their prominent optical property with high absorbance and scattering effects. By manipulating the scattering effect and adjusting the surface coating of GNRs, the researchers were able to identify changes in the optical property of M1 and M2 macrophages and utilize them as a parameter to monitor physiological changes.

The researchers used the flow cytometer (FCM) to capture changes in the granularity of the cells in order to identify GNR-laden macrophages and determine the specific scattering of GNRs. The FCM is generally used to identify a particular population of fluorescence-labeled cells, but in this case, it was used in label-free detection based only on scattering that came from the GNRs. With this unique method the researchers observed that one type of coating of GNRs exhibited greater selectivity towards M2 cells over M1.

"Our approach in utilizing the scattering of GNRs to identify M1 and M2 macrophages opens a new strategy in cellular identifications using FCM with the help of increased scattering of internalized nanoparticles," says Dr. Ruchira Chakraborty, leading researcher at Prof. Dror Fixler's laboratory at Bar-Ilan University's the Kofkin Faculty of Engineering and Institute of Nanotechnology and Advanced Materials. "Further development of this technique will lead us to build a new point of care or a biopsy tool which can predict the stages of manifestation of diseases like cancer, atherosclerosis, and fibrosis just from the simple tissue fluids or blood samples," says Prof. Dror Fixler, Director of the Bar-Ilan Nano Institute, who led the study in cooperation with Prof. Ran Kornowski and Dr. Dorit Leshem from Beilinson Hospital.
-end-
This study was funded by the Israel Science Foundation (ISF) and the Planning and Budgeting Committee of the Council for Higher Education in Israel.

Bar-Ilan University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.